rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Zavain Dar

Director

Company insider

Files Form 4 as: Director, Recursion Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
32
Buys
0
Sells
1
Bought
$0
Sold
$181K
Companies
1
Companies where not an officer
1
First trade
7 Dec 2021
Last trade
1 Oct 2026
Last filed
2 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
RXRX Recursion PharmaceuticalsDirector · Biotechnology · last 1 Oct 20260 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Oct 2026filed 2 Oct 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—4,607 at $0.00filing
1 Jul 2026filed 2 Jul 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—5,109 at $0.00filing
1 Jul 2026filed 2 Jul 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—5,109 at $0.00filing
17 Jun 2026filed 22 Jun 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—88,424 at $0.00filing
17 Jun 2026filed 22 Jun 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—88,424 at $0.00filing
1 Apr 2026filed 2 Apr 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—4,902 at $0.00filing
1 Apr 2026filed 2 Apr 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—4,902 at $0.00filing
2 Jan 2026filed 6 Jan 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—3,571 at $0.00filing
2 Jan 2026filed 6 Jan 2026RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—3,571 at $0.00filing
1 Oct 2025filed 3 Oct 2025RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—2,941 at $0.00filing
1 Jul 2025filed 3 Jul 2025RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—2,924 at $0.00filing
18 Jun 2025filed 23 Jun 2025RXRX Recursion Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—44,031 at $0.00filing
18 Jun 2025filed 23 Jun 2025RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—22,016 at $0.00filing
1 Apr 2025filed 3 Apr 2025RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—2,745 at $0.00filing
2 Jan 2025filed 6 Jan 2025RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—1,907 at $0.00filing
1 Oct 2024filed 4 Oct 2024RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—2,229 at $0.00filing
1 Jul 2024filed 3 Jul 2024RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—1,843 at $0.00filing
3 Jun 2024filed 5 Jun 2024RXRX Recursion Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—26,193 at $0.00filing
3 Jun 2024filed 5 Jun 2024RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—13,097 at $0.00filing
1 Apr 2024filed 3 Apr 2024RXRX Recursion PharmaceuticalsBiotechnologySEC FORM 4 Code A—1,467 at $0.00filing

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Blake BorgesonDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Robert HershbergDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Dean Y. LiDirector · Director at Recursion Pharmaceuticals, filing Form 4 there in the last year
Ben R. TaylorChief Financial Officer · Chief Financial Officer at Recursion Pharmaceuticals, filing Form 4 there in the last year
Najat KhanCEO and President · CEO and President at Recursion Pharmaceuticals, filing Form 4 there in the last year